Indeterminate observations (Liver Imaging Reporting and Data System category 3) on MRI in the cirrhotic liver: Fate and clinical implications

American Journal of Roentgenology

Volumn 201, Issue 5, 2013, Pages 993-1001

  Choi, Jin Young ^a   Cho, Hyun Cheol ^b   Sun, Mark ^c   Kim, Hyeon Chang ^d   Sirlin, Claude B ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Daegu Veterans Hospital   (South Korea)

^c UCSD MEDICAL CENTER   (United States)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Liver; Liver Imaging Reporting and Data System; MRI

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID;

ADULT; AGED; ARTICLE; CANCER SIZE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER IMAGING REPORTING AND DATA SYSTEM; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGNAL PROCESSING;

ADULT; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOLOGY INFORMATION SYSTEMS; RETROSPECTIVE STUDIES;

EID: 84886460183     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.10007     Document Type: Article

References (30)

1. Unoura M, Kaneko S, Matsushita E, et al. High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 1993; 40:305-310
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750
4. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007; 167:1983-1989
5. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022
6. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247:311-330
7. Yu JS, Chung JJ, Kim JH, Kim KW. Small hypervascular hepatocellular carcinomas: value of "washout" on gadolinium-enhanced dynamic MR imaging compared to superparamagnetic iron oxide-enhanced imaging. Eur Radiol 2009; 19:2614-2622
8. van den Bos IC, Hussain SM, Dwarkasing RS, et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 2007; 26:1548-1555
9. Kim TK, Lee KH, Jang HJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011; 259:730-738
10. American College of Radiology. Liver Imaging Reporting and Data System version 2013.1. American College of Radiology website. www.acr.org/Quality- Safety/Resources/LIRADS. Published March 2011. Updated 2013. Accessed June 21, 2013
11. Holland AE, Hecht EM, Hahn WY, et al. Importance of small (≤20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 2005; 237:938-944
12. Jeong YY, Mitchell DG, Kamishima T. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR 2002; 178:1327-1334
13. Shimizu A, Ito K, Koike S, Fujita T, Shimizu K, Matsunaga N. Cirrhosis or chronic hepatitis: evaluation of small (≤2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003; 226:550-555
14. Choi D, Mitchell DG, Verma SK, et al. Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations. Radiology 2007; 244:776-783
15. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 2011; 21:1233-1242
16. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255:459-466
17. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256:151-158
18. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acidenhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (<=2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45:96-103
19. Yu JS, Kim KW, Jeong MG, Lee JT, Yoo HS. Nontumorous hepatic arterial-portal venous shunts: MR imaging findings. Radiology 2000; 217:750-756
20. Ahn JH, Yu JS, Hwang SH, Chung JJ, Kim JH, Kim KW. Nontumorous arterioportal shunts in the liver: CT and MRI findings considering mechanisms and fate. Eur Radiol 2010; 20:385-394
21. Hwang SH, Yu JS, Kim KW, Kim JH, Chung JJ. Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. J Comput Assist Tomogr 2008; 32:39-45
22. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology 2009; 49:658-664
23. Park YN, Kim MJ. Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging 2011; 36:232-243
24. Khan AS, Hussain HK, Johnson TD, Weadock WJ, Pelletier SJ, Marrero JA. Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 2010; 32:360-366
25. Kim MJ. Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver 2011; 5:15-21
26. Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259-266
27. Taouli B, Goh JS, Lu Y, et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 2005; 29:425-429
28. Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis: a study in 22 patients. Gastroenterology 1986; 90:289-298
29. Okazaki N, Yoshino M, Yoshida T, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time: a preliminary report. Cancer 1989; 63:2207-2210
30. O'Malley ME, Takayama Y, Sherman M. Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease. Am J Gastroenterol 2005; 100:1523-1528